Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
PURPOSE: The purpose of this study is to define which visual acuity (VA) measurements are the best indicators of high-quality care for patients receiving intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD). METHODS: Analysis of prospectively collected data recorded with...
Váldodahkkit: | Ross, A, Donachie, P, Sallam, A, Stratton, I, Mohamed, Q, Scanlon, P, Kirkpatrick, J, Johnston, R |
---|---|
Materiálatiipa: | Journal article |
Giella: | English |
Almmustuhtton: |
2013
|
Geahča maid
-
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Dahkki: Chakravarthy, U, et al.
Almmustuhtton: (2012) -
Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab.
Dahkki: Sivaprasad, S, et al.
Almmustuhtton: (2011) -
Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
Dahkki: Rachel Hui Fen Lim, et al.
Almmustuhtton: (2017-03-01) -
Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
Dahkki: Joachim Wachtlin, et al.
Almmustuhtton: (2020-01-01) -
Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
Dahkki: Sun T, et al.
Almmustuhtton: (2021-06-01)